PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24944605-9	2014	DHMEQ was shown to antagonize the increasing levels of anti-nucleosome, anti-dsDNA and anti-histone autoantibodies, as well as the increasing levels of IL-1beta, 6 and 17 and TNF-alpha.	dehydroxymethylepoxyquinomicin	0-5	interleukin 1 beta	Mus musculus	152-160	
22161143-7	2012	Dehydroxy methyl epoxyquinomicin, a selective inhibitor of NFkappaB, partially inhibited the enhancement of fibronectin expression by TGF-beta, TNF-alpha, and IL-1beta, but not of N-cadherin expression.	dehydroxymethylepoxyquinomicin	0-32	interleukin 1 beta	Mus musculus	159-167	
23900151-11	2013	In sharp contrast, DHMEQ treatment markedly improved the normoglycemic rate, which was associated with the suppression of serum high mobility group complex-1 (HMGB1) and proinflammatory cytokines, including tumor necrosis factor-alpha, monocyte chemoattractant protein-1, macrophage inflammatory protein-1beta, interleukin-1beta, and interleukin-6, after PITx.	dehydroxymethylepoxyquinomicin	19-24	interleukin 1 beta	Mus musculus	311-328	
22325176-10	2012	mRNA expression levels of the pro-inflammatory cytokines, such as IL-1beta, TNF-alpha, IL-6, IL-12p40, IL-17, and MCP-1 were also suppressed by DHMEQ administration.	dehydroxymethylepoxyquinomicin	144-149	interleukin 1 beta	Mus musculus	66-74	
16978829-5	2006	Using enzyme-linked immunosorbent assays (ELISAs) we showed DHMEQ to inhibit LPS-induced secretion of IL-6, IL-12, interleukin-1beta (IL-1beta), and TNF-alpha.	dehydroxymethylepoxyquinomicin	60-65	interleukin 1 beta	Mus musculus	115-132	
16978829-5	2006	Using enzyme-linked immunosorbent assays (ELISAs) we showed DHMEQ to inhibit LPS-induced secretion of IL-6, IL-12, interleukin-1beta (IL-1beta), and TNF-alpha.	dehydroxymethylepoxyquinomicin	60-65	interleukin 1 beta	Mus musculus	134-142	
16978829-6	2006	Furthermore, DHMEQ also inhibited the phagocytosis of fluorescently labeled Escherichia coli by RAW264.7 cells treated with LPS or IL-1beta, thus being the first evidence for the involvement of NF-kappaB in the regulation of phagocytosis by use of this inhibitor.	dehydroxymethylepoxyquinomicin	13-18	interleukin 1 beta	Mus musculus	131-139	
30059880-9	2018	Blocking oxidative stress by administering melatonin or inhibiting NF-kappaB activation by treatment with Dehydroxymethylepoxyquinomicin effectively prevented increasing the levels IL-1beta, IL-17 and nerve growth factor.	dehydroxymethylepoxyquinomicin	106-136	interleukin 1 beta	Mus musculus	181-189